EcoDrugPlus

Cholecystokinin B Receptor

Ensembl ID : ENSBBBG00000003534
Gene Symbol: CCKBR
3 Cross references
270 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSBBBG00000005365
Gene Symbol: CHRM1
3 Cross references
104 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSBBBG00000015443
Gene Symbol: CHRM2
3 Cross references
261 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSBBBG00000007929
Gene Symbol: CHRM3
3 Cross references
257 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSBBBG00000014075
Gene Symbol: CHRM4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSBBBG00000012865
Gene Symbol: CHRM5
3 Cross references
264 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSBBBG00000010431
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSBBBG00000017847
Gene Symbol: CHRNA4
3 Cross references
206 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSBBBG00000010844
Gene Symbol: CHRNA7
3 Cross references
249 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSBBBG00000013928
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSBBBG00000010417
Gene Symbol: CHRNB4
1 Cross references
199 Possible Orthologues:

Chymase 1

Ensembl ID : ENSBBBG00000009814
Gene Symbol: CMA1
3 Cross references
280 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).